Plexxikon Launching Phase I/II Trial for PLX3397 in AML Patients with Flt3 Mutations | GenomeWeb

Originally published Dec. 12.

Plexxikon said this week that it is launching a Phase I/II trial to study the safety and efficacy of its drug candidate PLX3397 in AML patients whose tumors harbor cancer-driving Flt3 mutations, which occur in 20 percent to 30 percent of AML patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.